A new biologic drug has been given to a patient with pulmonary sarcoidosis for the first time. The drug, infliximab, was administered at the John Radcliffe Hospital, part of Oxford University ...

The first new drug approved for 50 years to treat a rare condition that creates swollen tissue on the lungs has been ...

A new study from Emory University has identified a biological connection between inflammation and deficits in motivation in individuals with schizophrenia, offering new hope for treating symptoms that ...

It can cause a wide range of symptoms, from abdominal pain to arthritis. Symptoms tend to follow a relapsing-remitting ...

This groundbreaking research, published in Molecular Psychiatry, found that an anti-inflammatory drug called infliximab may ...

Molecular-guided decision-making improves disease control and remission in the treatment of IBD with anti-TNF therapy, however, application to other therapies is questioned.

Now three, he has weekly injections of Methotrexate, which slows down the body's immune system and helps to reduce swelling ...

The primary endpoint of comprehensive disease control was defined as a combination of clinical remission (CDAI under 150; ...

In patients with IBD on maintenance IFX, use of 5-ASA and immunomodulators does not significantly reduce flares, infections, or adverse reactions.

South Korea’s Celltrion Healthcare has begun a UK trial of its infliximab biosimilar to see if the drug can accelerate recovery from symptoms of COVID-19. The company noted that COVID-19 is ...

South Korea’s Ministry of Food and Drug Safety approved 18 biosimilar products in 2024, making it a record year for domestic biosimilar approvals since the agency’s first nod of Celltrion Inc.’s ...

An increased risk of both invasive and superficial fungal infections was observed among patients who received TNF-α inhibitors for various conditions.